MCET.US Multicell Techs Inc
- Market cap
- USD 500K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Aug 2015.
Is MCET.US undervalued?
Graham numberThe Graham number of Multicell Techs Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Multicell Techs Inc fundamental analysis
No fundamental analysis for Multicell Techs Inc yet.
Multicell Techs Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Multicell Techs Inc
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent imm…
Full company profileMulticell Techs Inc financial statements
2015 annualized: Fiscal year 2015 is not finished. Income statement and cash flow are annualized from 3 quarters up to Aug 31, 2015, the balance sheet is the latest quarter. Figures change when the annual report is published.
Multicell Techs Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 252K | 210K | 174K | 529K | 49.3K | 49.3K | 49.32 | 49.32 | 1.06K |
| Gross Profit | - | - | - | - | 49.3K | 49.3K | 49.32 | 49.32 | 680.91 |
| Operating Income | - | - | - | - | -2.31M | -1.57M | -1.37K | -722.81 | -317.09 |
| EBITDA | - | - | - | - | - | - | -1.37M | -517K | -305K |
| Net Income | - | - | - | - | -1.80M | -1.26M | -1.23K | -380.07 | -333.69 |
| EPS | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||
| Total Assets | 1.69M | 57.0K | 410K | 677K | 721K | 211K | 179.09 | 126.22 | 296.01 |
| Total Liabilities | 2.49M | 2.50M | 2.11M | 2.69M | 2.31M | 1.81M | 1.28K | 1.62K | 1.54K |
| Shareholders' Equity | -793K | -2.44M | -1.70M | -2.02M | -1.59M | -1.60M | -344.77 | -118.55 | -250.69 |
| Cash & Short-term Investments | 412K | 6.00K | 397K | 634K | 405K | 199K | 146.21 | 112.53 | 281.12 |
| Total Debt | - | - | - | - | - | - | 107.10 | 202.58 | 149.08 |
| Cash Flow | |||||||||
| Operating Cash Flow | - | - | - | - | -1.24M | -890K | -1.25K | -1.09K | 135.99 |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54K |
| Free Cash Flow | - | - | - | - | - | - | -1.25K | -1.09K | 134.77 |
| Ratios | |||||||||
| ROA | - | - | - | - | -249.8% | -595.3% | -689.4% | -301.1% | -112.7% |
| Net Profit Margin | - | - | - | - | -3,651.1% | -2,547.2% | -2,503.3% | -770.6% | -31.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Multicell Techs Inc dividends
Multicell Techs Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:5 on May 20, 2005.
Who owns Multicell Techs Inc
- Insiders 9.99%
- Institutions 0.00%
- Public & others 90.01%
- Shares outstanding 5.00B
- Free float 4.50B
Multicell Techs Inc company profile
- Company name
- Multicell Techs Inc
- Ticker
- MCET.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- November
- Address
- 68 Cumberland Street, Woonsocket, RI, United States, 02895
- Phone
- 401 762 0045
- Website
- www.multicelltech.com
About Multicell Techs Inc
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.
Multicell Techs Inc management
2- Mr. W. Gerald NewminChairman, CEO, President, CFO, Treasurer & Secretary · born 1937
- Ms. Barbara CorbettManager of Investor Relations · born 1948